AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

13 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

08 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

03 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

18 дек 2024 06:00:00 Источник Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

08 дек 2024 11:40:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

11 ноя 2024 08:45:31 Источник NetDania Notify

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

08 ноя 2024 08:55:39 Источник NetDania Notify

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

07 ноя 2024 13:59:27 Источник NetDania Notify

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

05 ноя 2024 08:05:00 Источник Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

31 окт 2024 05:30:00 Источник Nasdaq GlobeNewswire

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

23 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

17 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

26 сен 2024 08:45:10 Источник NetDania Notify

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

11 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

05 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

06 авг 2024 16:50:17 Источник Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

01 авг 2024 05:31:00 Источник Nasdaq GlobeNewswire

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

01 авг 2024 05:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

23 июл 2024 09:53:30 Источник NetDania Notify

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

18 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire